rimonabant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| cannabinoid receptors antagonists | 4150 | 168273-06-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 20 | mg | O |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 19, 2006 | EMA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A08AX01 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Other antiobesity drugs |
| MeSH PA | D019440 | Anti-Obesity Agents |
| MeSH PA | D063387 | Cannabinoid Receptor Antagonists |
| MeSH PA | D063385 | Cannabinoid Receptor Modulators |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D018377 | Neurotransmitter Agents |
| CHEBI has role | CHEBI:73416 | CB1 receptor antagonists |
| CHEBI has role | CHEBI:74518 | anti-obestic agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Obesity | indication | 414916001 | DOID:9970 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.58 | acidic |
| pKa2 | 1.83 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Cannabinoid receptor 1 | GPCR | ANTAGONIST | Ki | 9.72 | CHEMBL | DRUG LABEL | |||
| Acetylcholinesterase | Enzyme | IC50 | 4.60 | CHEMBL | |||||
| Cannabinoid receptor 2 | GPCR | Ki | 8.96 | CHEMBL | |||||
| N-arachidonyl glycine receptor | GPCR | IC50 | 5 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.55 | CHEMBL | |||||
| G-protein coupled receptor 55 | GPCR | EC50 | 5.70 | CHEMBL | |||||
| Cannabinoid receptor 2 | GPCR | Ki | 6.43 | CHEMBL | |||||
| Cannabinoid receptor 1 | GPCR | Ki | 8.82 | CHEMBL | |||||
| Cannabinoid receptor 1 | GPCR | Ki | 9.51 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D05731 | KEGG_DRUG |
| C1142933 | UMLSCUI |
| CHEBI:34967 | CHEBI |
| AY6 | PDB_CHEM_ID |
| CHEMBL111 | ChEMBL_ID |
| CHEMBL558598 | ChEMBL_ID |
| D000077285 | MESH_DESCRIPTOR_UI |
| DB06155 | DRUGBANK_ID |
| 743 | IUPHAR_LIGAND_ID |
| 8029 | INN_ID |
| RML78EN3XE | UNII |
| 104850 | PUBCHEM_CID |
| 011633 | NDDF |
| 422589005 | SNOMEDCT_US |
| 422794008 | SNOMEDCT_US |
Pharmaceutical products:
None